MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee

Public Comment Policy

October 6, 2023

In accordance with the State of Mississippi's Open Meetings Act, the Mississippi Division of Medicaid (DOM) Pharmacy and Therapeutics (P&T) Committee meetings are open to the public. This law requires that a public announcement of the meetings be made two weeks prior to the scheduled meeting date. Except for specific pricing information, proprietary information or confidential information, the records of the P&T Committee are available to the public as well.

The purpose of this policy is to outline the P&T public comment process. DOM's goal is to continue to streamline the meeting processes, while providing an opportunity for comment from pharmaceutical industry representatives and other interested parties.

P&T Committee Policy for Public Comment

A. Public comment during the P&T Committee Meeting is not open to the general public. However representatives from the pharmaceutical industry and advocacy/special interest groups may register to speak in advance of the meeting.
B. Content is limited to drugs relevant to the drug classes on the agenda to be discussed during the meeting.
C. Registration prior to the date of the P&T Committee Meeting is required. Speakers may register up to one (1) month in advance of the meeting date.
D. Registered speakers must sign in at least ten (10) minutes prior to the start of the meeting; otherwise the speaker will not be permitted to speak during the public comment period.
E. Presentations
    a. The Chair will recognize the speakers according to the order in which they have registered.
    b. Speakers may only provide oral presentations; at no time may visual or audio aids be used.
    c. Per the request of the Committee, no written documents or handouts are to be provided to the Committee members prior to and/or during the meeting.
    d. Speakers representing pharmaceutical companies or advocacy groups shall limit their presentation to three (3) minutes per drug/per class/per manufacturer.
    e. The presentation should focus on the clinical advantages of the particular product and shall refrain from criticizing the products from competitors.
F. No questions or comments from the audience will be entertained unless approval is granted by two-thirds of the members present at the meeting.
G. The Committee reserves the right to suspend or eliminate the period for public comment if the privilege becomes abused or is deemed to be non-productive.